#Ministry of Biotechnology

[meret118]

In fact, Dalla Ragione has spent more than a decade scouring the masterpieces of 15th- and 16th-century art for answers to one of the great questions of Italian agriculture: Whatever happened to the boisterous selection of fruits that, for centuries, were a celebrated part of Italian cuisine and culture? Slowly and indefatigably, she has been rediscovering those fruits, first in archives and paintings and then, incredibly, in small forgotten plots across Italy. Her nonprofit, Archeologia Arborea, is helping farmers and governments around the world preserve and even bring back into cultivation all manner of forgotten fruits. In the process, Dalla Ragione has become a globally renowned fruit detective, by recognizing in her country’s Renaissance artworks not only exceptional examples of cultural patrimony but also hidden messages from a bygone era of genetic abundance that can offer clues about how to recover what was seemingly lost.

. . .

Six centuries ago, Italy boasted hundreds of varieties for every fruit, each adapted to specific ecological niches. Apple, pear and cherry varieties across Umbria were different, in subtle and not-so-subtle ways, from Venetian, Florentine or Piedmontese varieties. At the turn of the 20th century, the country was home to at least 1,000 pear varieties, according to Dalla Ragione. Today, Italy is one of Europe’s foremost producers of pears. Yet for both pears and apples, a mere four varieties each now compose more than 70 percent of the country’s production, compared with the hundreds of varieties that were common a century ago. A 2020 Atlas of Biodiversity commissioned by the Ministry of Agriculture—to which Dalla Ragione contributed—documents how dozens if not hundreds of varieties of peaches, cherries, grapes and apricots once cultivated in Italy’s many regions have shrunk to a handful of uniform varieties for each fruit nationwide.

The loss of those varieties isn’t just a question of lost deliciousness. It also means that we’ve lost centuries of adaptability encoded in the genes of the fruits of yesteryear. According to Mario Marino, an agronomist working with the Climate Change Division of the United Nations’ Food and Agriculture Organization, who serves on the board of advisers for Archeologia Arborea, rediscovering the descendants of those old fruits will be crucial for Italy’s ability to withstand the unpredictable and increasingly dramatic effects of climate change.

A tree in Dalla Ragione’s orchard bursts with cow-nose apples, like the one she spotted in Bellini’s Madonna With Child. They’re often mistaken for pears.

. . .

In 2017, Dalla Ragione obtained a PhD in biodiversity from the University of Perugia. For her doctoral thesis, she analyzed the genomes of hundreds of pear varieties, which led to a radical discovery: Older pears, dating back to the 15th century and earlier, have many more alleles—meaning more genetic diversity—than 21st-century varieties. “That diversity,” says Lorenzo Raggi, a researcher in agricultural genetics and biotechnologies at the University of Perugia, “can translate into a greater capacity to adapt to different conditions.” This genetic diversity also meant that there were huge differences among the fruits themselves, even those from the same roots. “One year the trees would produce fruits of one color, then the next year, another color,” Dalla Ragione says. It also gave these varieties the capacity to adapt to shifting conditions, generation after generation. They might not produce as much per tree as modern varieties, but their traits helped them survive new pests and changing weather conditions, meaning they produced fruit more steadily over decades and even centuries. 

. . .

“Industrial agriculture created a few varieties that are very productive in very precise conditions, with a lot of chemicals and a lot of water. The new varieties may be bigger and have more consistent color, but they have very few genes—few words. Their genetic patrimony is very simple. If you present the right question, they can answer, because maybe they have four or five or maybe ten words. But if you present other questions—like drought or climate change or other situations—they have no words to answer. They can’t answer because they do not have enough genetic variability inside to answer these questions. Old varieties have a big vocabulary. They have many words to answer these new questions.” 

[allthebrazilianpolitics]

Fiocruz and GEMMABio announce partnership for the development of gene therapies

Fiocruz and GEMMA Biotherapeutics (GEMMABio) announced last Tuesday (10/8) an agreement to sponsor research focused on gene therapy treatments for the Brazilian population within the scope of the Unified Health System (SUS). The ultimate goal of the international partnership with the company founded by gene therapy expert Jim Wilson is to obtain approval for gene therapy programs that will enable the country to increase the distribution of treatments for rare diseases at a more affordable cost.

With the support of the Ministry of Health (MS), the Foundation will invest up to US$100 million in GEMMABio over four years. The funds will be used to develop clinical research and production to expand the distribution of treatments for rare diseases in Brazil at a more affordable cost for the SUS.

"This partnership with GEMMABio reaffirms Fiocruz's commitment to innovation in health and its mission to ensure that scientific advances reach all Brazilians," said the Foundation's president, Mario Moreira. "By expanding access to gene therapies through the SUS, we are not only democratizing cutting-edge technologies, but also strengthening our ability to treat rare diseases in an affordable and effective manner. It is an important step to establish Brazil as a global reference in public health and innovation," he added.

"By combining our resources and expertise, this collaboration represents a major breakthrough in making gene therapies accessible to more patients faster and at a fraction of the usual cost," said Jim Wilson, president and CEO of GEMMABio. "We are optimistic that this agreement will serve as a global example for expanding access to advanced medical therapies, as well as for seeking non-traditional ways to capitalize biotechnology companies."

Continue reading.

[velocityinstitute]

What is NEET Exams in India ?

The National Eligibility cum Entrance Test (NEET) is a competitive examination in India for students aspiring to pursue undergraduate medical and dental courses (MBBS/BDS) in government or private medical colleges across the country. Here's a concise definition in 10 lines:

NEET is conducted by the National Testing Agency (NTA) on behalf of the Ministry of Education, Government of India.

It replaced multiple medical entrance exams previously held by various states and institutions, creating a single standardized test nationwide.

NEET evaluates a student's knowledge in physics, chemistry, and biology (botany and zoology).

The exam consists of multiple-choice questions and is conducted annually in multiple languages.

To be eligible for NEET, candidates must have completed 10+2 or equivalent with Physics, Chemistry, Biology/Biotechnology, and English.

There are also eligibility criteria regarding age limit and attempts.

NEET scores are used by both government and private medical colleges for admission to undergraduate medical programs.

The exam has a significant impact on the future career paths of aspiring medical professionals.

NEET aims to standardize the admission process, ensuring fairness and transparency.

Despite controversy and debates surrounding its implementation, NEET remains the primary entrance examination for medical aspirants in India.

[jehlumjk]

INSTITUTE OF LIFE SCIENCES ILS JRF WALK-IN-INTERVIEW ADVT NO 46/2024

INSTITUTE OF LIFE SCIENCES ILS JRF WALK-IN-INTERVIEW ADVT NO 46/2024. INSTITUTE OF LIFE SCIENCES   (An Autonomous Institute under the Dept. of Biotechnology, Ministry of Science & Technology, Govt. of India) NALCO Square, Bhubaneswar 751023, India.   WALK-IN-INTERVIEW   Advt. No. 46/2022   Date: 14.11.2024   Institute of Life Sciences (ILS), Bhubaneswar, an autonomous institute of the Department…

[latestmarketresearchnews]

Aptamers Market - Structure, Size, Trends, Analysis and Outlook 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. This rapid growth is being driven by significant advancements in the development, purification, and drug delivery systems for targeting and eliminating harmful cells, which have garnered the attention of researchers. Aptamers possess several competitive advantages over traditional antibodies, including smaller molecular size, lower immunogenicity (reduced immune response), reduced manufacturing costs, and fewer side effects. These benefits are encouraging research and development (R&D) efforts in the creation of new aptamers, fueling market expansion.

Despite considerable research, no highly effective treatments for COVID-19 have been identified, partly due to the virus's extensive genetic mutations. However, biotechnological approaches, including the use of aptamers, hold promise in combating COVID-19 infections. Nucleic acid-based aptamers and peptide aptamers are believed to offer potential therapeutic solutions for the virus, and various government initiatives are supporting the development of novel treatments for COVID-19. For example, in September 2020, the Department of Community & Economic Development awarded USD 320,000 to Aptagen LLC to fund research and development of a novel COVID-19 treatment. This investment reflects the growing recognition of aptamers' potential in addressing unmet medical needs.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Aptamers are also proving valuable in diagnostics. Using SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, aptamer-based diagnostic kits and assays can develop high-affinity neutralizers and bioprobes for detecting SARS-CoV-2 and other COVID-19 biomarkers. These innovations are expected to further drive market growth. For example, in December 2021, Achiko AG received approval from the Indonesian Ministry of Health for its COVID-19 diagnostic kit, Aptamex. Aptamex is a second-generation, cost-effective diagnostic tool based on DNA aptamer technology, representing an emerging solution in healthcare diagnostics.

Type Segmentation Insights:

The aptamers market is segmented into nucleic acid aptamers and peptide aptamers. In 2022, the nucleic acid aptamers segment dominated the market, holding a 78.19% share, and is expected to exhibit the highest growth during the forecast period. Many companies are actively exploring the therapeutic mechanisms of nucleic acid aptamers for treating various disorders, such as age-related macular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted IVERIC BIO (formerly Ophthotech Corporation) a written agreement under the Special Protocol Assessment (SPA) for the design of its phase 3 clinical trial, GATHER2. The trial aims to assess the efficacy of Zimura, a nucleic acid aptamer-based drug, for patients with geographic atrophy (GA) secondary to AMD. This FDA approval is expected to significantly bolster the growth of the nucleic acid aptamer segment.

The peptide aptamer segment is anticipated to experience substantial growth, with a projected CAGR of 22.77% from 2023 to 2030, driven by its broad applications in diagnostics and therapeutics. For instance, in August 2021, scientists from the Engineering Center for Microtechnology and Diagnostics developed an innovative biosensor for multiparametric express testing in the preclinical diagnostics of cardiovascular diseases. This testing uses next-generation biochips, which are based on a peptide aptamer marker system and molecular recognition technology. The researchers designed peptide aptamers using data from the Data Bank and Protein 3D software. The introduction of such advanced products in the market is likely to increase the utilization of peptide aptamers, contributing to the segment's growth.

In summary, the aptamers market is poised for rapid expansion due to the advantages of aptamers in therapeutic and diagnostic applications, advancements in technology, and ongoing R&D efforts. The market's growth is further supported by government initiatives, regulatory approvals, and the increasing use of aptamer-based solutions in areas such as COVID-19 treatment, diagnostics, and the management of other medical conditions.

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[keanchee]

Breaking New Ground in Regenerative Medicine: MSC Therapy in Malaysia

Regenerative medicine is an evolving field that aims to repair or replace damaged tissues and organs, offering hope for conditions that currently lack effective treatments. Among the various approaches, Mesenchymal Stem Cell (MSC) therapy has gained significant traction, particularly in Malaysia. This innovative therapy harnesses the regenerative potential of MSCs to treat a range of diseases, from orthopaedic injuries to degenerative disorders.

Understanding Mesenchymal Stem Cells

Mesenchymal stem cells are multipotent stem cells derived from various tissues, including bone marrow, adipose tissue, and umbilical cord. They possess unique properties, such as the ability to differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. Additionally, MSCs secrete bioactive molecules that modulate immune responses, promote tissue repair, and reduce inflammation, making them a promising tool in regenerative medicine.

The Rise of MSC Therapy in Malaysia

In recent years, Malaysia has emerged as a hub for MSC therapy research and clinical applications. The country boasts advanced healthcare infrastructure and a growing number of research institutions dedicated to stem cell research. Collaborations between universities, hospitals, and biotechnology companies have accelerated the translation of MSC research into clinical practice. Furthermore, the Malaysian government has recognized the potential of regenerative medicine, investing in initiatives to support stem cell research and its applications.

Clinical Applications of MSC Therapy

Orthopedic Conditions

One of the most promising applications of MSC therapy is in the treatment of orthopedic conditions. Injuries such as fractures, cartilage damage, and osteoarthritis often lead to chronic pain and disability. MSCs can enhance the healing process by promoting the regeneration of bone and cartilage. Clinical trials conducted in Malaysia have shown positive outcomes, with patients experiencing reduced pain and improved mobility following MSC therapy.

Neurological Disorders

MSCs also hold potential for treating neurological disorders, including stroke, spinal cord injuries, and neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. Research indicates that MSCs can differentiate into neural cells and release neuroprotective factors that promote neuronal survival and regeneration. Malaysian researchers are actively exploring these applications, conducting clinical studies to evaluate the safety and efficacy of MSC therapy in neurological patients.

Cardiovascular Diseases

Another area of interest is the use of MSCs in treating cardiovascular diseases. Heart conditions such as ischemic heart disease and heart failure can benefit from MSC therapy, as these cells can improve cardiac function and promote tissue repair following injury. In Malaysia, innovative clinical trials are underway to assess the impact of MSC therapy on heart health, paving the way for new treatment protocols.

Regulatory Framework and Challenges

While MSC therapy shows great promise, several challenges must be addressed. The regulatory landscape surrounding stem cell therapies is complex and varies by region. In Malaysia, the National Institute of Health (NIH) and the Ministry of Health play crucial roles in regulating stem cell research and clinical applications. Researchers and healthcare providers must navigate these regulations to ensure that MSC therapies are safe and effective.

Additionally, public awareness and acceptance of MSC therapy are essential for its growth. Education and outreach initiatives are needed to inform the public about the benefits and risks associated with stem cell therapies. Addressing misconceptions and providing transparent information can foster trust and encourage patients to consider MSC therapy as a viable treatment option.

The Future of MSC Therapy in Malaysia

The future of MSC therapy in Malaysia looks promising. Ongoing research and clinical trials are expected to enhance our understanding of MSCs and their therapeutic potential. As the scientific community continues to explore new applications and refine treatment protocols, MSC therapy could become a standard of care for various conditions.

In conclusion, MSC therapy represents a groundbreaking advancement in regenerative medicine in Malaysia. With its potential to address unmet medical needs and improve patient outcomes, MSC therapy is poised to play a crucial role in the future of healthcare. Continued investment in research, collaboration among stakeholders, and a robust regulatory framework will be vital in realizing the full potential of this innovative therapy. As Malaysia advances in this field, it stands to make significant contributions to the global landscape of regenerative medicine.

[sudheervanguri]

The BioCare 2024 Fellowship is a prestigious program aimed at empowering women researchers in the field of biotechnology. This initiative, led by the Department of Biotechnology, Government of India, is designed to provide support for women scientists who are currently unemployed and looking to advance their careers in life sciences, biotechnology, and allied fields. The fellowship is open to Indian nationals, and the application deadline is December 1, 2024. If you're a woman researcher with a Ph.D. or M.Tech in biotechnology or life sciences, this is your chance to apply for the BioCare 2024 Fellowship and take a significant step forward in your scientific career. Eligibility Criteria for BioCare 2024 Fellowship To be considered for the BioCare 2024 Fellowship, candidates must meet the following eligibility requirements: Indian Women Nationals residing in India, aged up to 55 years. Applicants should be unemployed at the time of application submission. The program is divided into two categories: Category I: Women with a Ph.D. in any discipline of Biotechnology, Life Sciences, MD, MDS, M.V.Sc, or interdisciplinary sciences. Category II: Women with M.Tech in Biotechnology, M.Pharm, or equivalent degrees. Additionally, candidates already registered in higher studies or receiving other fellowships are not eligible to apply. The fellowship is also limited to those applying for their first extramural research grant—previous recipients of any government research grant as Principal Investigators are excluded. Fellowship Details and Nature of Support Selected fellows will receive a consolidated grant, which includes both recurring and non-recurring expenses to support the execution of the proposed research project. The fellowship will also cover financial support for the duration of the project, which can last up to a maximum of 3 years. This program is specifically aimed at helping women researchers who are not in a regular job position. As a BioCare fellow, you will have the opportunity to work on innovative research projects in areas such as: Communicable and Non-communicable Diseases Microbiome Research in Human Health and Disease Vaccines and Drug Development Nanotechnology-based Diagnostic and Therapeutic Tools Other emerging research topics within biotechnology and life sciences. [caption id="attachment_107297" align="aligncenter" width="640"] Application for BioCare 2024 Fellowship | Biotechnology Career Advancement[/caption] How to Apply for the BioCare 2024 Fellowship Interested candidates can submit their applications via the Common Fellowship Portal of the Ministry of Science & Technology. Follow these steps to apply: Visit the official application portal: https://fellowships.gov.in. Review the Terms & Conditions for the BioCare program on the Department of Biotechnology's website: https://dbtindia.gov.in. Complete the online application before the deadline on December 1, 2024. For additional support and queries, candidates may reach out to: Dr. Manoj Singh Rohilla, Scientist-F, Department of Biotechnology, Ministry of Science & Technology, New Delhi. Email: biocare-pmu@dbt.nic.in Phone: +91-11-24363726 Or contact the DBT-Human Resource Development Project Management Unit (PMU) located at the Regional Centre for Biotechnology, Faridabad, Haryana. Email: biocare.dbt@rcb.res.in Phone: +91-129-2848535 Don’t miss out—apply before December 1, 2024, and take your career to the next level!

[industrynewsupdates]

Genomics Market Business Growth, Opportunities and Forecast 2024-2030

The global genomics market size was valued at USD 32.65 billion in 2023 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030. 

The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.

Gather more insights about the market drivers, restrains and growth of the Genomics Market 

The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19.  For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.

Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.

The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).

The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.

The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.

Genomics Market Segmentation

Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:

Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Functional Genomics

• Transfection

• Real-Time PCR

• RNA Interference

• Mutational Analysis

• SNP Analysis

• Microarray Analysis

• Epigenomics

• Bisulfite Sequencing

• Chromatin Immunoprecipitation (ChIP & ChIP-Seq)

• Methylated DNA Immunoprecipitation (MeDIP)

• High-Resolution Melt (HRM)

• Chromatin Accessibility Assays

• Microarray Analysis

• Pathway Analysis

• Bead-Based Analysis

• Microarray Analysis

• Real-time PCR

• Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)

• Biomarker Discovery

• Mass Spectrometry

• Real-time PCR

• Microarray Analysis

• Statistical Analysis

• Bioinformatics

• DNA Sequencing

• Others

Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Sequencing

• PCR

• Flow Cytometry

• Microarrays

• Other technologies

Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)

• Products

o Instruments/Systems/Software

o Consumables & Reagents

• Services

o NGS-based Services

o Core Genomics Services

o Biomarker Translation Services

o Computational Services

o Others

End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Clinical Research

• Academic & Government Institutes

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other End Users

Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global cell sorting market size was valued at USD 242.7 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030. 

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

Key Companies & Market Share Insights

The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key Genomics Companies:

• Agilent Technologies

• Bio-Rad Laboratories, Inc.

• BGI Genomics

• Color Genomics, Inc.

• Danaher Corporation

• Eppendorf AG

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd.

• GE Healthcare

• Illumina, Inc.

• Myriad Genetics, Inc.

• Oxford Nanopore Technologies

• Pacific Biosciences of California, Inc.

• QIAGEN N.V.

• Quest Diagnostics Incorporated

• Thermo Fisher Scientific, Inc.

• 23andMe, Inc.

Recent Development

• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

• In February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region

• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.

• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies 

Order a free sample PDF of the Genomics Market Intelligence Study, published by Grand View Research.

[amrutatbrc1]

Biorational Market By Product Type, By Manufacturers, By End-User And Market Trend Analysis Forecast 2033

The biorational global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Biorational Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The biorational market size has grown rapidly in recent years. It will grow from $3.9 billion in 2023 to $4.56 billion in 2024 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to increased awareness about environmental concerns , the negative impacts of chemical pesticides , eco-friendly agricultural practices.

The biorational market size is expected to see rapid growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to regulatory support, the push for organic farming, the desire to reduce chemical residues in food. Major trends in the forecast period include advancements in research, increasing adoption of integrated pest management (ipm) strategies, technological advancements, improved formulations.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/biorational-global-market-report

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers - Increasing adoption of integrated pest management is driving the demand for biorational products going forward. Integrated Pest Management is a system of managing pests that has been designed to be sustainable. Integrated pest management involves using the best combination of cultural, biological, and chemical measures for particular circumstances, including plant biotechnology as appropriate. The use of biorational products for the management of insect pests has grown intensively, which has increased its popularity. The Government of India has adopted integrated pest management (IPM) as the main plank of plant protection in the Crop Production Programme. For instance, according to the Government of India Ministry of Agriculture and Farmers Welfare, in 2021, crop yield has been increased from 6.72–40.14% in rice and 22.7–26.63% in cotton in integrated pest management fields when compared to non-integrated pest management fields. Therefore, the increasing adoption of integrated pest management will drive the growth of the biorational market.

Market Trends - Product innovations have emerged as the key trend gaining popularity in the 5G chipset market. The major players in the market are developing innovative products for market growth. For instance, in June 2021, Samsung Electronics, a South Korea-based electronics company, developed 3GPP Rel.16 compliant chipsets, a range of next-generation 5G chipsets that deliver cutting-edge 5G technologies. The new chipsets consist of a second-generation 5G modem System-on-Chip (SoC), a third-generation mmWave Radio Frequency Integrated Circuit (RFIC) chip, and a Digital Front End (DFE)-RFIC integrated chip. These are designed to increase power efficiency, boost performance, and reduce the size of 5G solutions.

The biorational market covered in this report is segmented –

1) By Product Type: Botanicals, Semiochemicals, Other Product Types 2) By Formulation: Liquid, Dry 3) By Crop Type: Cereals and Grains, Fruits and Vegetables, Other Crop Types 4) By Application: Agriculture, Aquaculture, Structural Pest Control, Other Applications

Get an inside scoop of the biorational market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=6742&type=smp

Regional Insights - North America was the largest region in the biorational market in 2023. The regions covered in the biorational market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Key Companies - Major companies operating in the biorational market report are Isagro S. p. A., Summit Chemical Company, Gowan Company LLC, BASF SE, Suterra LLC, McLaughlin Gormley King Company, Marrone Bio Innovations Inc., Biological Control Products LLC, Russell IPM Ltd., Valent BioSciences LLC, Sumitomo Chemical Company Limited, Certis USA LLC, BioWorks Inc., Koppert Biological Systems B. V., Vestaron Corporation, Andermatt Group AG, AgBiTech Pty Ltd., e-nema GmbH, Novozymes A/S, Nufarm Limited, OHP Inc., Sipcam Agro USA Inc., Verdera Oy, STK Bio-ag Technologies, Cedar Chemicals LLC, Pherobank BV, Exosect Ltd., Shin-Etsu Chemical Co. Ltd., AgriSense-BCS Ltd.

Table of Contents 1. Executive Summary 2. Biorational Market Report Structure 3. Biorational Market Trends And Strategies 4. Biorational Market – Macro Economic Scenario 5. Biorational Market Size And Growth ….. 27. Biorational Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[mordorintelligencemarketresearch]

Navigating the Colombia Cold Chain Logistics Industry: Trends, Challenges, and Opportunities

Introduction The Colombia cold chain logistics market is projected to be valued at USD 2.10 billion in 2024 and is anticipated to grow to USD 3.87 billion by 2029. This represents a compound annual growth rate (CAGR) of 10.70% during the forecast period from 2024 to 2029.

Cold chain logistics plays a vital role in ensuring that temperature-sensitive products are stored, transported, and delivered safely. In Colombia, this sector is becoming increasingly critical due to the country’s rich agricultural resources and a growing pharmaceutical industry. This blog will explore the current state of Colombia's cold chain logistics market, examining key drivers, challenges, and future opportunities.

1. Overview of the Cold Chain Logistics Market in Colombia

Cold chain logistics refers to a temperature-controlled supply chain, essential for preserving the quality and safety of perishable goods. In Colombia, the cold chain market is projected to grow significantly, driven by rising consumer demand for fresh produce and pharmaceuticals. Recent market research indicates a CAGR of around 8% over the next five years, reflecting robust growth potential.

2. Key Sectors Driving Demand

Food and Beverage: With Colombia being one of the largest producers of coffee, fruits, and vegetables in Latin America, the demand for effective cold chain logistics is paramount. Ensuring products remain fresh during transport is critical for minimizing waste and maximizing profits.

Pharmaceuticals: The pharmaceutical sector is rapidly expanding, with increasing investments in biotechnology and healthcare. This sector requires stringent temperature control, with a focus on maintaining the efficacy of medications during transport.

E-commerce: The rise of online shopping, particularly in the wake of the pandemic, has transformed consumer expectations. The ability to deliver perishable goods swiftly and safely is now a competitive edge for e-commerce platforms.

3. Regulatory Landscape

Colombia’s cold chain logistics industry is regulated by several agencies that ensure compliance with health and safety standards. The Ministry of Health and the Colombian Institute for Technical Standards and Certification (ICONTEC) play crucial roles in establishing guidelines. Compliance with international standards such as those set by the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) is essential for companies looking to export products.

4. Technological Advancements

Technological innovations are reshaping the cold chain landscape.

IoT Devices: Temperature and humidity sensors enable real-time monitoring, ensuring that products remain within specified parameters.

Blockchain Technology: This technology enhances transparency and traceability, providing stakeholders with secure and tamper-proof records of the supply chain.

Automated Warehousing: Automated systems streamline operations, reduce labor costs, and minimize human error in temperature-sensitive storage.

5. Challenges Facing the Industry

Infrastructure Issues: While urban areas may have sufficient cold storage facilities, rural regions often lack adequate infrastructure. This disparity can lead to inefficiencies and increased costs.

Investment Gaps: Many cold chain providers struggle with outdated equipment and technology. There is a pressing need for investment to modernize facilities and processes.

Climate Change: Fluctuating weather patterns can impact logistics, particularly in rural areas where power outages can disrupt temperature control.

6. Opportunities for Growth

Investment Opportunities: There is significant potential for investors in cold storage facilities, refrigerated transport, and technology upgrades. Public-private partnerships could further drive innovation.

Sustainability Initiatives: Companies are increasingly focusing on sustainable practices, such as energy-efficient refrigeration and eco-friendly packaging. This shift not only meets consumer demand but also aligns with global sustainability goals.

Emerging Markets: Expanding into underserved areas presents a unique opportunity for companies to capture new customer bases and enhance service offerings.

7. Case Studies

Case Study 1: Major Logistics Provider: Highlight a leading logistics company that has successfully implemented advanced cold chain solutions, showcasing their strategies and results.

Case Study 2: Innovative Start-up: Feature a start-up disrupting the market with cutting-edge technology or unique business models, demonstrating how they are addressing industry challenges.

8. Future Outlook

The future of cold chain logistics in Colombia looks promising, with increasing integration of digital technologies. As consumer preferences evolve, companies must adapt to maintain competitiveness. Expect to see further emphasis on automation, data analytics, and enhanced customer experiences in the coming years.

Conclusion

In summary, the cold chain logistics market in Colombia is on an upward trajectory, driven by demand from key sectors and technological advancements. However, challenges remain that require collaborative efforts from stakeholders. As the industry evolves, embracing innovation and sustainable practices will be crucial for capitalizing on the growth potential in this dynamic market. For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/colombia-cold-chain-logistics-market

[iasguidance]

BioE3 Policy for fostering High-Performance Biomanufacturing approved by Union Cabinet

Context: Union Cabinet led by Prime Minister has approved the ‘BioE3’ (Biotechnology for Economy, Environment & Employment) Policy for Fostering High Performance Biomanufacturing of Department of Biotechnology under Ministry of Science & Technology.  Biomanufacturing Biomanufacturing refers to the use of engineered microbial, plant and animal (including human) cells with increasing precision…

[allthebrazilianpolitics]

Brazil Army colonel faces chop after speaking in putschist audios

Army Colonel Elcio Franco is set to be dismissed as advisor to the Brazilian Company of Blood Products and Biotechnology (Hemobras), linked to the Health Ministry, after it emerged he suggested moving Army troops to carry out a coup d’état in favor of former President Jair Bolsonaro last year. 

Mr. Franco served as the number two in the Health Ministry under Mr. Bolsonaro between 2020 and 2021, during the worst moments of the Covid pandemic in Brazil. He was appointed as the main negotiator in the allegedly fraudulent purchase of Covaxin vaccines. 

This week, CNN Brasil released audio recordings dating from December 2022, in which Mr. Franco tells Ailton Barros, a former army captain understood to be close with Mr. Bolsonaro, about the mobilization of 1,500 men for a putschist riot. The two men also complain about the Army command’s resistance to following this plan. 

Continue reading.

[tamanna31]

Aptamers Market Share, Supply, Sales, Manufacturers, Competitor and Consumption 2023 to 2030

Aptamers Industry Overview

The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030.

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

The aptamers based diagnostic kits and assays developed by using SELEX technology have the ability to develop high-affinity neutralizers and bioprobes for monitoring SARS-COV-2 & COVID-19 biomarkers. Therefore, the introduction of diagnostic kits in the market for disease diagnosis is projected to drive market growth. For instance, in December 2021, Achiko AG received approval from the Ministry of Health of the Republic of Indonesia for Aptamex, a COVID-19 diagnostic kit. Aptamex is a second-generation diagnostic kit developed by using DNA aptamer-based technology that is a cost-effective, chemically synthesized, and an emerging diagnostic kit for healthcare.

Aptamers based diagnostic products are the preferred choice among diagnostic and pathology labs for the diagnosis of disease at the cellular level due to their small size, high specificity, selectivity, and efficacy. Thus, increasing prevalence of diseases such as cancer, CVD, and AMD may increase the footfall of patients in labs for the diagnosis of these diseases, consequently, increasing demand for aptamer based diagnostic products. According to Cancer Research UK estimates, around 27.5 million people are expected to be diagnosed with cancer by 2040.

In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute in market growth by addressing the increased demand.

As of now, Macugen developed by Eyetech Pharmaceuticals, Inc., (currently commercialized by Bausch Health Companies Inc.) is only the U.S. FDA approved (2004) therapeutic aptamer available in the market. It is used for the treatment of age-related muscular degeneration disorder (AMD). Technological advancements in research encourage scientists’ attention towards the development of novel aptamer based therapeutic drugs for the treatment of various diseases. Currently, there are a number of products under different clinical trials including Zimura developed by IVERIC Bio, Inc., for the treatment of patients with drug AMD. Thus, expected approval of this drug may boost the growth of the market over the period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global structural biology & molecular modeling techniques market size was valued at USD 7.13 billion in 2023 and is projected to grow at a CAGR of 15.4% from 2024 to 2030.

• The global targeted DNA RNA sequencing market size was valued at USD 10.12 billion in 2023 and is projected to grow at a CAGR of 19.4% from 2024 to 2030.

Global Aptamers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the aptamers market on the basis of type, application, and region.

Type Outlook (Revenue, USD Million; 2018 - 2030)

Nucleic Acid Aptamer

Peptide Aptamer

Application Outlook (Revenue, USD Million; 2018 - 2030)

Diagnostics

Therapeutics

Research & Development

Others

Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics. Some of the prominent players in the global aptamers market include:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[jehlumjk]

INSTITUTE OF LIFE SCIENCES ILS JRF FELLOWSHIPS ADVT NO 45/2024

INSTITUTE OF LIFE SCIENCES ILS JRF FELLOWSHIPS ADVT NO 45/2024. INSTITUTE OF LIFE SCIENCES   (An Autonomous Institute under the Dept. of Biotechnology, Ministry of Science & Technology, Govt. of India) Nalco Square, Bhubaneswar 751023, India   Advt. No.: 45/2024   Date: 05-Nov-2024   Institute of Life Sciences (ILS), Bhubaneswar, an autonomous Institute of the Department of Biotechnology,…

[jobustad]

Latest PCSIR Jobs in Islamabad August 2024-Pakistan Council of Scientific & Industrial Research Jobs

Latest PCSIR Jobs in Islamabad August 2024 has been announce through Latest advertisement PCSIR, an R&D Organization working under the Federal Ministry of Science and Technology, Islamabad, requires the following staff for its project “Establishment of Medical Cannabis Greenhouses For Biotechnology Derived Bio-products, National Hemp & Cannabis Analytical Laboratory and National Industrial Hemp &…

[palmoilnews]

PALM OIL PRICES RISK UNCOMPETITIVENESS WITHOUT WPL REVISION BANGI, July 4 (Bernama) -- The price of palm oil will become uncompetitive compared to other producing countries if the windfall profit levy (WPL) on palm oil in this country is not revised. Plantation and Commodities Minister Datuk Seri Johari Abdul Ghani stated that his ministry would examine and review the WPL, with the findings to be submitted to the Ministry of Finance (MoF). "Let the MoF review this so we can reassess and indirectly encourage replanting. When this product becomes competitive, more investors will be attracted to the land we have," he told reporters after the launch of the Transfer of Technology (TOT) 2024 event here today. Yesterday, during a question-and-answer session in the Dewan Rakyat, Johari said the ministry would collaborate with the MPOB to review the WPL on palm oil for Budget 2025, aligning with the current commodity prices. "Previously, the cost of producing one metric tonne of palm oil was approximately RM1,800, but now it ranges from RM2,800 to RM3,200, depending on the size. "The cost structure at RM1,800 may have been suitable for WPL, but it is no longer appropriate when the market trades at about RM3,800 to RM3,900, with costs exceeding RM3,000," he said. Johari said industry players need to actively utilise the latest technology to increase production to ensure Malaysia's palm oil sector remains competitive and relevant in line with global changes. "The profits reaped should be reinvested so that the country's palm industry can improve," he said. MPOB also introduced six new technologies and one new service for commercialisation. Johari said these encompass the biotechnology cluster, mechanisation and automation and oleochemicals. He said the six technologies and new services introduced for commercialisation encompass the biotechnology cluster, mechanisation and automation, and oleochemicals. The six new technologies are the Clonal Palm Series 4 (CPS4) clones, radio-controlled hydrostatic flail mower, palm-based food-grade biodegradable grease, palm-based industrial liquid cleaners, palm-based sticky glue for household and plantation pest control as well as palm-based transformer oil. The new service introduced is the oil palm pest and rodent biocontrol service. Johari said the new technologies and innovations developed by the MPOB are in line with the growth of the palm industry's ecosystem and the expansion of the use of palm-based products in the market. "This initiative also allows the entrepreneurs to explore business opportunities in the palm sector," he said. The minister also launched MPBO TECH as the registered branding to empower the MPOB technology that has been commercialised.